Cardiology

An overlooked aspect of an under-discussed condition, Andrea Dunaif, MD, provided an overview of the cardiovascular risk seen among women with polycystic ovary syndrome.

How inclisiran, bempedoic acid, and other investigative therapies may contribute to cardiometabolic disease management.

The cardiologist discusses the lagging nature of US health care authorization and recommendation for already proven agents in cardiovascular risk reduction.

Research shows direct associations between unmanaged, severe OSA and cardiovascular event incidence. An expert reviews mechanisms and cross-sectional studies.

Though select diabetes guidelines suggest the use of continuous glucose monitoring on patients with diabetic patients on intensive therapy, the potential benefits on type 2 patients without insulin and pre-diabetes patients has yet to be fully explored.

Our latest case report from Brady Pregerson, MD, features an elderly woman with a history of diabetes experiencing sweats, light-headedness, nausea, and SOB. Can you determine the correct diagnosis?

Though limited data exist, Dr. Dunfaif believes there’s are indications of cardiovascular risk in patients of all ages with polycystic ovary syndrome.

Women with gestational diabetes face a twice greater risk of developing cardiovascular disease. Investigators are still seeking understanding of the association.

From evidence-based and plant-based diets, to promising new strategies involving SGLT2 inhibitors, Dr. Taub detailed preventative strategies used to combat cardiovascular disease.

A look at how European experts have shaped risk assessment through demographic-centric algorithms.

Dr. Grunberger believes that the improved time in range brought on by continual glucose monitoring could lead to a reduction in hypoglycemia and risk of cardiovascular events, as well as promising monetary benefits for patients and payers.

While some treatments did not result in reduced instances of strokes in patients, others such as GLP-1 agonists provided Dr. Inzucchi with new opportunities for cardiovascular disease prevention.

Updates to the ADA Standards of Medical Care emphasize the utility of SGLT2 inhibitors and GLP-1 agonists. Yet, initiation is lacking from prescribers.

An expert weighs in on improving guidelines to reflect optimal real-world care for patients at high risk of cardiovascular events.

Dr. Donna H. Ryan presents data on emerging pharmacological strategies that could aid patients in achieving optimal weight loss and prevent risk of cardiovascular events and diabetes.

Despite having lower burden of several cardiovasculard disease risk factors, cardiovascular mortality is higher in African Americans, which Dr. Dagogo-Jack attributes to disparities in patient care.

Dr. Peter Grant admits that the phenotypes surrounding certain cardiovascular diseases are complex, but notes treatments can be recommended based on individual patients’ complications.

Though the trial observing dapagliflozin for severe COVID-19 did not achieve statistical significance, investigators believe it showed the agent's benefit in acute illness.

In his presentation at TMIOA, Dr. Inzucchi referenced several diabetes medications and glucose management methods that resulted in a reduction of stroke risk in patients.

Announced in a statement on September 1, the FDA warning is an update to the FDA Drug Safety Communication issued on February 4, 2021 and the results of a review of a trial that found a serious increased risk of CV-related events with the drug.

Our latest cardiology case report from Brady Pregerson, MD, features an elderly man brought to the emergency department as a code STEMI from home for altered mental status and shortness of breath. Can you determine the correct diagnosis?

Overall positive genetic test results for variants was 10.1% for patients diagnosed with AF before 66 years of age and 16.8% in patients diagnosed before 30 years of age.

Announced in a statement from TransMedics Group Inc. on September 7, premarket approval to the OCS Heart System could allow for broader utilization of donor hearts for transplantation in the US.

Editorial advisory board member Dr. Paul Thompson reflects on how advances in diabetes management have impacted cardiovascular medicine and why staying abreast of these advances is essential to being a cardiologist in 2021.

Dr. Paul Thompson reflects on how advances in diabetes management have bled over into the field of cardiology and offers perspective on why he believes staying abreast of these advances is an integral part of being a cardiologist today.